Zobrazeno 1 - 10
of 10
pro vyhledávání: '"Mia‐Louise Nielsen"'
Autor:
Mia‐Louise Nielsen, Troels C. Petersen, Julia‐Tatjana Maul, Jashin J. Wu, Trine Bertelsen, Lone Skov, Simon F. Thomsen, Jacob P. Thyssen, Alexander Egeberg
Publikováno v:
JEADV Clinical Practice, Vol 2, Iss 4, Pp 792-801 (2023)
Abstract Background Some patients treated with biologic therapy for psoriasis experience adverse events causing treatment discontinuation. Objectives To identify predictors of adverse events resulting in discontinuation of biologics for psoriasis. Me
Externí odkaz:
https://doaj.org/article/6cec022e83ed4456a16df050d8c8cca3
Autor:
David Thein, Nana A. L. Rosenø, Mia‐Louise Nielsen, Lars Erik Kristensen, Julia‐Tatjana Maul, Jashin J. Wu, Simon Francis Thomsen, Jacob P. Thyssen, Alexander Egeberg
Publikováno v:
JEADV Clinical Practice, Vol 2, Iss 4, Pp 857-863 (2023)
Abstract Background Limited research has been conducted on whether advances in novel biologics and biosimilars have improved the treatment journey preceding biologics. Objectives To map the overall treatment journey preceding the initiation of first
Externí odkaz:
https://doaj.org/article/6abf915d987d47869945d2dafe4986f2
Autor:
Julia-Tatjana Maul, Lara W. Maul, Johannes A. Didaskalu, Fernando Valenzuela, Ricardo Romiti, Hannah Peterson, Edwin Korouri, Farah Novoa, Hazel H. Oon, Min Zheng, Jashin J. Wu, Jacob P. Thyssen, Alexander Egeberg, April W. Armstrong, Mia-Louise Nielsen
Publikováno v:
Acta Dermato-Venereologica, Vol 104 (2024)
Quality of life impairment in dermatology patients and severity of psoriasis are quantified by the Dermatology Life Quality Index (DLQI) and the Psoriasis Area and Severity Index (PASI), respectively. The aim of this study is to compare the correlati
Externí odkaz:
https://doaj.org/article/250b855fe0a040b5b1d82a06984980a1
Autor:
Lara Valeska Maul, Anna Sophie Jahn, Gustavo S P Pamplona, Markus Streit, Lorena Gantenbein, Simon Müller, Mia-Louise Nielsen, Christian Greis, Alexander A Navarini, Julia-Tatjana Maul
Publikováno v:
JMIR Dermatology, Vol 6, p e45384 (2023)
BackgroundTeledermatology is currently finding its place in modern health care worldwide as a rapidly evolving field. ObjectiveThe aim of this study was to investigate the acceptance of teledermatology compared to in-person consultation from the per
Externí odkaz:
https://doaj.org/article/6ef1eadcd0a44013859b4622d25e5a9d
Autor:
Mia-Louise Nielsen, David Thein, Mads Kirchheiner Rasmussen, Trine Bertelsen, Tomas Norman Dam, Lone Skov, Lars Erik Bryld, Jashin J. Wu, Simon Francis Thomsen, Jacob P. Thyssen, Alexander Egeberg
Publikováno v:
Nielsen, M-L, Thein, D, Rasmussen, M K, Bertelsen, T, Dam, T N, Skov, L, Bryld, L E, Wu, J J, Thomsen, S F, Thyssen, J P & Egeberg, A 2023, ' Trajectories and prognosis after discontinuation of biologics due to remission in psoriasis-a nationwide cohort study ', Journal of the American Academy of Dermatology, vol. 88, no. 6, pp. 1378-1381 . https://doi.org/10.1016/j.jaad.2023.01.029
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6ea49db38d4a885dad2780ec29f7d98c
https://pure.au.dk/portal/da/publications/trajectories-and-prognosis-after-discontinuation-of-biologics-due-to-remission-in-psoriasis--a-nationwide-cohort-study(ea713dc8-6f16-44f2-8095-be53271aaf3a).html
https://pure.au.dk/portal/da/publications/trajectories-and-prognosis-after-discontinuation-of-biologics-due-to-remission-in-psoriasis--a-nationwide-cohort-study(ea713dc8-6f16-44f2-8095-be53271aaf3a).html
The road to biologics in patients with hidradenitis suppurativa: a nationwide drug utilization study
Autor:
Hans Christian Ring, Yiqiu Yao, Julia-Tatjana Maul, John R. Ingram, John W. Frew, Jonathan Thorsen, Mia-Louise Nielsen, Jashin J. Wu, Jacob P. Thyssen, Simon F. Thomsen, Alexander Egeberg
Publikováno v:
Ring, H C, Yao, Y, Maul, J T, Ingram, J R, Frew, J W, Thorsen, J, Nielsen, M L, Wu, J J, Thyssen, J P, Thomsen, S F & Egeberg, A 2022, ' The road to biologics in patients with hidradenitis suppurativa : a nationwide drug utilization study ', British Journal of Dermatology, vol. 187, no. 4, pp. 523-530 . https://doi.org/10.1111/bjd.21673
SUMMARY Background Prolonged systemic antibiotic treatment is often a part of management of hidradenitis suppurativa (HS). Although biologic therapies are now available, the patient’s treatment journey leading to biologic therapy is unclear. Object
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::03e16ac658d853dfbdb09bb3e8a163c9
https://doi.org/10.5167/uzh-227870
https://doi.org/10.5167/uzh-227870
Autor:
Mia-Louise Nielsen, Troels Christian Petersen, Julia-Tatjana Maul, Jashin J. Wu, Mads Kirchheiner Rasmussen, Trine Bertelsen, Kawa Khaled Ajgeiy, Lone Skov, Simon Francis Thomsen, Jacob P. Thyssen, Alexander Egeberg
Publikováno v:
Nielsen, M-L, Petersen, T C, Maul, J-T, Wu, J J, Rasmussen, M K, Bertelsen, T, Ajgeiy, K K, Skov, L, Thomsen, S F, Thyssen, J P & Egeberg, A 2022, ' Multivariable Predictive Models to Identify the Optimal Biologic Therapy for Treatment of Patients With Psoriasis at the Individual Level ', JAMA Dermatology, vol. 158, no. 10, pp. 1149-1156 . https://doi.org/10.1001/jamadermatol.2022.3171
ImportanceIdentifying the optimal long-term biologic therapy for patients with psoriasis is often done through trial and error.ObjectiveTo identify the optimal biologic therapy for individual patients with psoriasis using predictive statistical and m
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0d5eab4dcf6828b0894557d417ce2bcf
https://pure.au.dk/portal/da/publications/multivariable-predictive-models-to-identify-the-optimal-biologic-therapy-for-treatment-of-patients-with-psoriasis-at-the-individual-level(66fecd37-919e-491a-ae3b-7c48572bad2c).html
https://pure.au.dk/portal/da/publications/multivariable-predictive-models-to-identify-the-optimal-biologic-therapy-for-treatment-of-patients-with-psoriasis-at-the-individual-level(66fecd37-919e-491a-ae3b-7c48572bad2c).html
Autor:
Mette Gyldenløve, Howraman Meteran, Jennifer A. Sørensen, Simon Fage, Yiqiu Yao, Jesper Lindhardsen, Christoffer V. Nissen, Tanja Todberg, Simon F. Thomsen, Lone Skov, Claus Zachariae, Lars Iversen, Mia-Louise Nielsen, Alexander Egeberg
Publikováno v:
Gyldenløve, M, Meteran, H, Sørensen, J A, Fage, S, Yao, Y, Lindhardsen, J, Nissen, C V, Todberg, T, Thomsen, S F, Skov, L, Zachariae, C, Iversen, L, Nielsen, M L & Egeberg, A 2023, ' Efficacy and safety of oral roflumilast for moderate-to-severe psoriasis—a randomized controlled trial (PSORRO) ', The Lancet Regional Health-Europe, vol. 30, 100639 . https://doi.org/10.1016/j.lanepe.2023.100639
Background: Roflumilast is a targeted inhibitor of phosphodiesterase (PDE)-4 and has been approved for treatment of severe chronic obstructive pulmonary disease for more than a decade. Generic versions are available in the United States. PDE-4 is inv
Autor:
Lea Nymand, Mia-Louise Nielsen, Alexander Egeberg, Simon Francis Thomsen, Jacob Pontoppidan Thyssen
Publikováno v:
Nielsen, M-L, Nymand, L K, Thomsen, S F, Thyssen, J P & Egeberg, A 2022, ' Delay in diagnosis and treatment of patients with psoriasis : a population-based cross-sectional study ', British Journal of Dermatology, vol. 187, no. 4, pp. 590-591 . https://doi.org/10.1111/bjd.21594
Autor:
Alexander Egeberg, Nana Aviaaja Lippert Rosenø, David Aagaard, Erik Hillo Lørup, Mia-Louise Nielsen, Lea Nymand, Lars Erik Kristensen, Jacob P. Thyssen, Simon Francis Thomsen, Rene Lindholm Cordtz, Nikolai Loft, Lone Skov, Lars Erik Bryld, Mads Kirchheiner Rasmussen, Pil Højgaard, Salome Kristensen, Lene Dreyer
Publikováno v:
Egeberg, A, Rosenø, N A L, Aagaard, D, Lørup, E H, Nielsen, M-L, Nymand, L, Kristensen, L E, Thyssen, J P, Thomsen, S F, Cordtz, R L, Loft, N, Skov, L, Bryld, L E, Rasmussen, M K, Højgaard, P, Kristensen, S & Dreyer, L 2022, ' Drug survival of biologics and novel immunomodulators for rheumatoid arthritis, axial spondyloarthritis, psoriatic arthritis, and psoriasis-A nationwide cohort study from the DANBIO and DERMBIO registries ', Seminars in Arthritis and Rheumatism, vol. 53, 151979 . https://doi.org/10.1016/j.semarthrit.2022.151979
Egeberg, A, Rosenø, N A L, Aagaard, D, Lørup, E H, Nielsen, M-L, Nymand, L, Kristensen, L E, Thyssen, J P, Thomsen, S F, Cordtz, R L, Loft, N, Skov, L, Bryld, L E, Rasmussen, M K, Højgaard, P, Kristensen, S & Dreyer, L 2022, ' Drug survival of biologics and novel immunomodulators for rheumatoid arthritis, axial spondyloarthritis, psoriatic arthritis, and psoriasis-A nationwide cohort study from the DANBIO and DERMBIO registries ', Seminars in Arthritis and Rheumatism, vol. 53, pp. 151979 . https://doi.org/10.1016/j.semarthrit.2022.151979
Egeberg, A, Rosenø, N A L, Aagaard, D, Lørup, E H, Nielsen, M L, Nymand, L, Kristensen, L E, Thyssen, J P, Thomsen, S F, Cordtz, R L, Loft, N, Skov, L, Bryld, L E, Rasmussen, M K, Højgaard, P, Kristensen, S & Dreyer, L 2022, ' Drug survival of biologics and novel immunomodulators for rheumatoid arthritis, axial spondyloarthritis, psoriatic arthritis, and psoriasis-A nationwide cohort study from the DANBIO and DERMBIO registries ', Seminars in Arthritis and Rheumatism, vol. 53, 151979 . https://doi.org/10.1016/j.semarthrit.2022.151979
Egeberg, A, Rosenø, N A L, Aagaard, D, Lørup, E H, Nielsen, M-L, Nymand, L, Kristensen, L E, Thyssen, J P, Thomsen, S F, Cordtz, R L, Loft, N, Skov, L, Bryld, L E, Rasmussen, M K, Højgaard, P, Kristensen, S & Dreyer, L 2022, ' Drug survival of biologics and novel immunomodulators for rheumatoid arthritis, axial spondyloarthritis, psoriatic arthritis, and psoriasis-A nationwide cohort study from the DANBIO and DERMBIO registries ', Seminars in Arthritis and Rheumatism, vol. 53, pp. 151979 . https://doi.org/10.1016/j.semarthrit.2022.151979
Egeberg, A, Rosenø, N A L, Aagaard, D, Lørup, E H, Nielsen, M L, Nymand, L, Kristensen, L E, Thyssen, J P, Thomsen, S F, Cordtz, R L, Loft, N, Skov, L, Bryld, L E, Rasmussen, M K, Højgaard, P, Kristensen, S & Dreyer, L 2022, ' Drug survival of biologics and novel immunomodulators for rheumatoid arthritis, axial spondyloarthritis, psoriatic arthritis, and psoriasis-A nationwide cohort study from the DANBIO and DERMBIO registries ', Seminars in Arthritis and Rheumatism, vol. 53, 151979 . https://doi.org/10.1016/j.semarthrit.2022.151979
OBJECTIVE: Drug survival is an important proxy measure for effectiveness of treatments for inflammatory diseases such as rheumatoid arthritis (RA), axial spondyloarthritis (AxSpA), psoriatic arthritis (PsA), and psoriasis. The objective of this study